Kymera Therapeutics Q3 2024 GAAP EPS $(0.82) Beats $(0.84) Estimate, Sales $3.740M Miss $10.360M Estimate
Portfolio Pulse from Benzinga Newsdesk
Kymera Therapeutics reported a Q3 2024 GAAP EPS of $(0.82), beating the estimate of $(0.84), but sales of $3.740M missed the $10.360M estimate. EPS improved from last year's $(0.90), but sales decreased by 20.90% from $4.728M.
October 31, 2024 | 11:34 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Kymera Therapeutics' Q3 2024 EPS of $(0.82) beat expectations, but sales of $3.740M significantly missed the $10.360M estimate. While EPS improved from last year, sales decreased by 20.90%.
The EPS beat suggests some positive operational efficiency, but the significant miss in sales indicates potential issues in revenue generation or market demand. The decrease in sales compared to last year further supports a negative short-term impact on stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100